[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20030718A1 - Lactamas como antagonistas de taquiquininas - Google Patents

Lactamas como antagonistas de taquiquininas

Info

Publication number
PE20030718A1
PE20030718A1 PE2002001201A PE2002001201A PE20030718A1 PE 20030718 A1 PE20030718 A1 PE 20030718A1 PE 2002001201 A PE2002001201 A PE 2002001201A PE 2002001201 A PE2002001201 A PE 2002001201A PE 20030718 A1 PE20030718 A1 PE 20030718A1
Authority
PE
Peru
Prior art keywords
het
antagonists
aryl
heterocycle
piperidinone
Prior art date
Application number
PE2002001201A
Other languages
English (en)
Inventor
Alan Stobie
Donald Stuart Middleton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030718A1 publication Critical patent/PE20030718A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A LACTAMAS DE FORMULA I DONDE R ES HET-a; R1 ES FENILO; m ES 1-4; Z ES N(R3)(R4X); N(R3)Y, HETEROCICLO OPCIONALMENTE ESPIROCONDENSADO; Y ES ARILO, HET-b, HET-c, HETEROCICLO; X ES NR3R5, OR3, O-ARILO-1, O-HETb, O-HETc, ENTRE OTROS; R3 Y R6 SON H, ALQUILO; R4 Y R7 SON ALQUILENO; R5 ES COOR3, S(O)pR3, S(O)pARILO-1, ENTRE OTROS; HET b ES UN HETEROCICLO; HET-a Y HET-c SON HETEROCICLO AROMATICO; ARILO-1 ES FENILO, NAFTILO; p ES 0-2; n ES 0-4; SON COMPUESTOS PREFERIOS (5S)-5-(3,4-DICLOROFENIL)-1-(6-METIL-2-PIRIDINIL)-5-{2-[3-(4-MORFOLINIL)-1-AZETIDINIL]ETIL}-2-PIPERIDINONA; (5S)-5-(3,4-DICLOROFENIL)-1-(6-METIL-2-PIRIDINIL)-5-{2-[3-(4-HIDROXIPIPERIDINIL)-1-AZETIDINIL]ETIL}-2-PIPERIDINONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A UNA COMPOSICION QUE COMPRENDE ADEMAS ANTAGONISTAS MUSCARINICOS, ANTAGONISTAS DE ALFA ADRENORECEPTORES, INHIBIDORES DE LA RECAPTACION DE SEROTONINA, ENTRE OTROS. LOS COMPUESTOS SON ANTAGONISTAS DE TAQUIQUININAS Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES ANTIINFLAMATORIAS, TRASTORNO DEL SISTEMA NERVIOSO CENTRAL, GASTROINTESTINAL, ENFERMEDAD CAUSADA POR HELICOBACTER PYLORI, AFECCIONES UROLOGICAS
PE2002001201A 2001-12-18 2002-12-12 Lactamas como antagonistas de taquiquininas PE20030718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0130261.1A GB0130261D0 (en) 2001-12-18 2001-12-18 Lactams as tachykinin antagonists

Publications (1)

Publication Number Publication Date
PE20030718A1 true PE20030718A1 (es) 2003-08-18

Family

ID=9927858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001201A PE20030718A1 (es) 2001-12-18 2002-12-12 Lactamas como antagonistas de taquiquininas

Country Status (16)

Country Link
US (1) US7060836B2 (es)
EP (1) EP1456200A1 (es)
JP (1) JP2005514389A (es)
AR (1) AR037852A1 (es)
AU (1) AU2002366320A1 (es)
BR (1) BR0215017A (es)
CA (1) CA2470236A1 (es)
GB (1) GB0130261D0 (es)
GT (1) GT200200280A (es)
HN (1) HN2002000365A (es)
MX (1) MXPA04005221A (es)
PA (1) PA8561501A1 (es)
PE (1) PE20030718A1 (es)
TW (1) TW200302097A (es)
UY (1) UY27588A1 (es)
WO (1) WO2003051868A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199250B2 (en) 2002-12-20 2007-04-03 Battelle Memorial Institute Process for producing cyclic compounds
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JP2008521821A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
EP1943250A1 (en) 2005-09-09 2008-07-16 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
JP5205971B2 (ja) * 2006-01-27 2013-06-05 宇部興産株式会社 テトラヒドロピラン化合物の製造方法
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
EP2021005A4 (en) * 2006-05-03 2009-11-25 Cnsbio Pty Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US7592345B2 (en) * 2007-06-13 2009-09-22 Hoffmann-La Roche Inc. Piperazine and [1,4]diazepan derivatives as NK antagonists
EP2175886A1 (en) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
KR101174980B1 (ko) * 2007-09-14 2012-08-17 에프. 호프만-라 로슈 아게 Ｎｋ３ 수용체 길항제로서의 피페리딘 유도체
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2688403B1 (en) * 2011-03-23 2017-05-31 Trevena, Inc. Opioid receptor ligands and methods of using and making same
AU2016372028B2 (en) 2015-12-14 2022-02-17 Trevena, Inc. Methods of treating hyperalgesia
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112321599B (zh) * 2020-11-25 2023-05-30 合肥远志医药科技开发有限公司 一种药物中间体7-氧代-2-氮杂螺[3.5]壬烷的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
US20040132710A1 (en) 2004-07-08
GB0130261D0 (en) 2002-02-06
CA2470236A1 (en) 2003-06-26
GT200200280A (es) 2003-07-11
AU2002366320A1 (en) 2003-06-30
BR0215017A (pt) 2004-08-31
PA8561501A1 (es) 2003-07-28
WO2003051868A1 (en) 2003-06-26
MXPA04005221A (es) 2004-08-19
JP2005514389A (ja) 2005-05-19
TW200302097A (en) 2003-08-01
HN2002000365A (es) 2003-07-23
UY27588A1 (es) 2003-07-31
AR037852A1 (es) 2004-12-09
US7060836B2 (en) 2006-06-13
EP1456200A1 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20091095A1 (es) Moduladores de gamma secretasa
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
PE20021006A1 (es) Derivados de 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la proteinquinasa
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
PE20030702A1 (es) Inhibidores de pde9 para tratamiento de transtornos cardiovasculares
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
PA8520301A1 (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
RU2007140737A (ru) Пиразолы
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
AR067991A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
PE20020063A1 (es) Bis-arilsulfonas como ligandos del receptor de 5-ht
PE20040666A1 (es) Derivados novedosos de piperidina

Legal Events

Date Code Title Description
FC Refusal